GlobeNewswire Inc.··NaMesoblast Wins FDA Green Light for Direct Path to DMD Approval Trial
Mesoblast receives IND clearance to proceed directly to registrational trial for Ryoncil in Duchenne muscular dystrophy, potentially accelerating path to market approval.
MESORyoncil®cell therapy